An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge

Dengue Clinical Trial

Official title:

A Phase 2a, Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 3 Infection in a Dengue Human Challenge Model in Healthy Adult Participants

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05048875
• Other study ID #: CIR 332
• Secondary ID: 15629564281802DN
• Status: Recruiting
• Phase: Phase 2
• Start date: February 3, 2022
• Est. completion date: August 2024

Study information

• Verified date: November 2023
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 54
• Est. completion date: August 2024
• Est. primary completion date: May 16, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria for receipt of Study Drug:

1. Male or female.

2. 18 to 55 years of age, inclusive, at time of screening.

3. Healthy on the basis of physical examination, medical history, and vital signs performed at screening.

4. Healthy on the basis of clinical laboratory tests performed at screening.

5. Must pass the comprehension assessment indicating that the participant understands the purpose, procedures, and potential risks and benefits of the study, after reading the informed consent and after the investigator or designee has provided detailed information on the study and answered the potential participant's questions.

6. Must have a body mass index between 18.0 and 35.0 kg/m2, inclusive.

7. Must have a normal electrocardiogram (ECG, test which displays a person's heartbeat) at screening.

8. Must have a blood pressure (after lying face up for greater than or equal to 5 minutes) between 90 and 140 mmHg systolic and less than or equal to 90 mmHg diastolic at screening.

9. Must complete the informed consent process independently and without assistance and sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.

10. All persons of childbearing potential must have a negative pregnancy test at screening.

11. A volunteer must be:

1. Not of childbearing potential, or

2. Of childbearing potential and practicing a highly effective, preferably user independent method of contraception and agrees to remain on a highly effective method while receiving study drug and until 90 days after the last dose of study drug.

12. A person of childbearing potential must agree not to donate eggs for the purposes of assisted reproduction during the study and for 90 days after the last dose of study drug.

13. During the study and for 90 days after the last dose of study drug, persons who are having sexual relationships in which their partner may become pregnant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person. Persons who are having sexual relationships in which their partner may become pregnant should also be advised of the benefit for their partner to use a highly effective method of contraception as condoms may break or leak.

14. A sperm-producing participant must agree not to donate sperm for the purpose of reproduction during the study and for 90 days after the last dose of study drug.

15. Must be willing and able to adhere to the study requirements and lifestyle restrictions:

• Do not take any restricted medications/treatments

• Agree to follow all study requirements

• No unusual strenuous exercise

• Must not donate blood or blood products within 6 months after last dose of study drug

• Must not participate in another investigational study during the study or within 90 days after last dose of study drug

• Must not travel to any dengue-endemic region (as defined by the United States Centers for Disease Control and Prevention

• Must limit the use of food or drinks/beverages containing alcohol to the absolute minimum from 48 hours before first dose of study drug until Day 85.

• Must refrain from consumption of grapefruit or grapefruit juice, energy drinks, excessive use of caffeine from 7 days before first dose of study drug until Day 85

• May not use drugs of abuse (including amphetamine, barbiturate, cocaine, methadone, and opiates) until 3 weeks after the last dose of study drug.

• Should not consume any food containing poppy seeds or codeine-containing formulation starting 72 hours before the screening visits and before any visit during the follow-up phase (to avoid a false-positive urine drug test).

• Should follow the instructions for the timing of the standardized meals

16. Available for the duration of the study, which is approximately 85 days after injection of the dengue virus.

Exclusion Criteria for receipt of Study Drug:

1. History of liver or renal impairment; significant cardiac, vascular, pulmonary, gastrointestinal (such as significant diarrhea, constipation lasting greater than 2 days), endocrine, neurologic, hematologic, rheumatologic, neoplastic, autoimmune, or metabolic disturbances.

2. Known allergies, hypersensitivity, or intolerance to the study drug (JNJ-64281802) or its inactive substances, or an acute, life threatening allergic reaction or swelling following study drug administration.

3. History of a severe allergic reaction or anaphylaxis (which is a severe, potentially life-threatening allergic reaction).

4. Taken any substances or therapies that are not allowed before the first dose of study drug.

5. Received an investigational intervention or participated in another investigational clinical trial (including investigational vaccines) within 6 months before first dose of study drug, or is currently enrolled in an investigational study, or is planning to be enrolled in an investigational study within 90 days after last dose of study drug. With the exception of participation in COVID-19 vaccine trials and receipt COVID-19 vaccines licensed or under Emergency Use Authorization which can be received at any time.

6. Persons of childbearing potential only: Pregnant as determined by a positive pregnancy blood test, breastfeeding, or planning to become pregnant during the study or within 90 days after last dose of study drug.

7. Plans to impregnate and help conceive a child during the study or within 90 days after last dose of study drug.

8. Any condition for which, in the opinion of the study doctor, participation would not be in the best interest of the participant.

9. Blood test confirming current infection with human immunodeficiency virus type 1 or 2 (HIV-1 or HIV-2), hepatitis B virus (HBV), or hepatitis C virus (HCV), or blood test confirming past or current infection with any of the following flaviviruses: dengue, Zika virus (ZIKV), West Nile virus, or St. Louis Encephalitis (SLE) virus or vaccination for dengue, Zika virus, or Japanese Encephalitis virus (JEV) Note: Blood laboratory testing will assess the presence of antibodies at screening.

10. Recent (in the past 4 weeks) travel to any dengue-endemic region (as defined by the US CDC) or having definite plans to travel to a dengue endemic region, during the study. Potential participants may be eligible for enrollment greater than or equal to 4 weeks after their return from a dengue-endemic region.

11. Received or plans to receive:

1. Licensed live attenuated vaccines - within 28 days before first dose of study drug until 28 days after last dose of study drug.

2. Other licensed (not live) vaccines - within 14 days before first dose of study drug until 14 days after last dose of study drug.

3. COVID-19 vaccines, either licensed or under EUA, are allowed at any time during the study however every effort will be made to avoid the above windows of time of administration.

Note: Vaccinations against DENV and Zika virus are not allowed until 90 days after last dose of study drug.

12. Employee of the study doctor or study site with direct involvement in the proposed study or other studies under the direction of that study doctor or study site, as well as family members of the employees or the investigator.

13. Any clinically relevant skin disease in the past 6 months, such as active dermatitis, active eczema, drug rash, psoriasis, and urticaria.

14. Having donated or lost greater than 1 unit of blood (500 mL) within 30 days or greater than 1 unit of plasma (250 mL) within 7 days before first dose of study drug or having the intention to donate blood or blood products during the study and within 6 months after last dose of study drug.

15. Receipt of blood products within the past 6 months of initiation of study drug or anticipated receipt of any blood products during the 28 days following dengue virus injection.

16. Known or suspected congenital or acquired immunodeficiency or use of immunosuppressive corticosteroids (excluding topical and nasal) or immunosuppressive drugs within 28 days before first dose of study drug until 28 days following the last dose of study drug.

a. An immunosuppressive dose of corticosteroids is defined as greater than or equal to10 mg prednisone equivalent per day for grater than or equal to 14 days.

17. Use of any strong cytochrome P450 (CYP) 3A4 inhibitors (eg, clarithromycin, itraconazole), CYP3A4 inducers (eg, phenytoin, rifampin), or substrates for CYP3A4 (eg, midazolam, triazolam), CYP2C8 (eg, repaglinide), CYP2C9 (eg, warfarin, tolbutamide), BCRP (eg Pravastatin and folic acid), or CYP2C19 (eg, S-mephenytoin, omeprazole) within 14 days before first dose of study drug. Certain other medications are allowed including metformin, levothyroxine, H1 and H2 receptor antagonists, weak CYP3A4 inhibitors, selective serotonin reuptake inhibitors, selective norepinephrine reuptake inhibitors, tricyclic anti-depressants, anxiolytics, and benzodiazepines.

18. Any significant alcohol or drug abuse in the past 12 months that has caused medical, occupational, or family problems, as indicated by participant history, or positive test result(s) for drugs of abuse (including amphetamine, barbiturate, benzodiazepine, cocaine, methadone, and opiates) at screening.

19. Behavioral, cognitive, or psychiatric disease that affects the subject's ability to understand and cooperate with the requirements of the study protocol.

20. Severe asthma (emergency room visit or hospitalization within the last 6 months).

21. Asplenia (the absence of a spleen).

22. Refusal to allow specimen storage for future research.

23. History of risk factors for life-threatening heart rhythm disturbance which includes heart failure, low potassium levels in the blood, family history of fast, chaotic heartbeats known as Long QT Syndrome.

Exclusion Criteria for dengue virus injection:

1. Body temperature greater than or equal to 38.0°C (100.4°F), confirmed by repeat measurements at least 10 minutes after the first measurement.

2. Acute illness.

3. Any other clinical or laboratory finding that would exclude the participant from inoculation (including, but limited to, a positive urine/serum pregnancy test), as assessed by the study doctor.

Related Conditions & MeSH terms

• Dengue

Intervention

Drug:
• JNJ-64281802 (sentinel high dose)
Group 1a, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
• JNJ-64281802 (remaining high dose)
Group 1b, JNJ-64281802 (high dose: 600-mg loading dose for 5 days/200-mg maintenance dose for 21 days)
• JNJ-64281802 (medium/low dose)
Group 2, JNJ-64281802 (low dose: 40-mg loading dose for 5 days/10-mg maintenance dose for 21 days) AND JNJ-64281802 (medium dose: 200-mg loading dose for 5 days/50-mg maintenance dose for 21 days)
• JNJ-64281802 (daily dosing regimen X)
Group 3, JNJ-64281802 (800-mg twice per day loading dose for 2 days/250-mg maintenance dose for 21 days)
• JNJ-64281802 (weekly dosing regimen Y1)
Group 4, JNJ-64281802 (450-mg twice per day loading dose for 2 days/1200-mg maintenance dose weekly [3 doses over 15 days])
• JNJ-64281802 (weekly dosing regimen Z2)
Group 5, JNJ-64281802 (250-mg twice per day loading dose for 2 days/500-mg maintenance dose weekly [3 doses over 15 days])
• Placebo
No therapeutic effect, used as a control in testing new drugs

Locations

Country	Name	City	State
United States	Johns Hopkins University, Bloomberg School of Public Health	Baltimore	Maryland
United States	University of Vermont Medical Center (UVMMC), Clinical Research Center	Burlington	Vermont

Sponsors (3)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)	Janssen, LP, National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assess the antiviral activity of the study drug (JNJ 64281802) versus placebo in terms of reduction of dengue infection.	Area under the DENV-3 RNA viral load (VL) concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29.	29 days
Secondary	Number of adverse events to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	Physical examinations to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	Recording of vital signs to assess the safety and tolerability of the study drug (JNJ 64281802).	Body temperature will be recorded twice daily by study staff and/or by the participants from Day 1 up to and including Day 29; pulse (bpm), systolic and diastolic blood pressure (mmHg) measured on each clinic visit.	99 weeks
Secondary	12-lead ECG with measurement of QTcF to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	12-lead ECG with measurement of QRS interval to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	12-lead ECG with measurement of PR interval to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	Clinical laboratory assessments to assess the safety and tolerability of the study drug (JNJ 64281802).		99 weeks
Secondary	Assess the dengue infection-associated Adverse Events (unwanted medical occurrence).	Occurrence and severity of DENV infection associated AEs.	99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo by reviewing the area under the log10-transformed DENV 3 RNA VL concentration-time curves from immediately before inoculation (baseline on Day 1) until Day 29 (AUCD1 D29 [log10 VL])		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo by reviewing the peak of detectable DENV-3 RNA (log10 VL).		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo for duration in days of detectable DENV-3 RNA.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo time to first onset by days of detectable DENV 3 RNA.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo based on presence of detectable DENV-3 RNA as measured by PCR (log10 VL) or culture (log10 VL).		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo on area under the infectious viremia curves from immediately before inoculation (baseline on Day 1) until Day 29.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo on the area under the log10-transformed viremia curves.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo peak of detectable viremia level		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo on the duration of detectable viremia.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo on time to first onset of detectable viremia.		99 weeks
Secondary	Antiviral activity of the study drug (JNJ 64281802) versus placebo on presence of detectable viremia.		99 weeks
Secondary	Assess how the body handles the study drug (JNJ-64281802) following repeated oral dosing. Using Pharmacokinetic analysis from repeated blood samples taken at specified time points after drug administration during 2 inpatient stays.	Blood samples will be taken for measurement of plasma concentrations of JNJ-64281802 at specific time points in the study. Additional PK sampling may be performed on the non-intensive PK days (eg, in the event of an overdose) on other time points, in consultation with the JNJ drug development team.; Plasma samples will be analyzed to determine concentrations of JNJ-64281802 using a validated, specific, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method under the supervision of the DDT's Bioanalytical Laboratory Department of Bioanalysis.	99 weeks
Secondary	Cmax: maximum observed analyte concentration of JNJ-64281802		99 weeks
Secondary	Cmin: minimum observed analyte concentration of JNJ-64281802		99 weeks
Secondary	Ctrough: observed analyte concentration just before the beginning or at the end of a dosing interval of JNJ-64281802		99 weeks
Secondary	Cavg: average analyte concentration over the dosing interval (t) calculated as AUCt/t of JNJ-64281802		99 weeks
Secondary	tmax: the actual sampling time to reach the maximum observed analyte concentration of JNJ-64281802		99 weeks
Secondary	FI: percentage fluctuation (variation) between maximum and minimum analyte concentration at steady-state, calculated as 100 x ([Cmax - Cmin] / Cavg) of JNJ-64281802		99 weeks
Secondary	AUCt: area under the plasma concentration-time curve during the dosing interval (t hours); calculated by linear-linear trapezoidal summation of JNJ-64281802		99 weeks
Secondary	Occurrence and magnitude of anti-DENV-3 total IgM antibody titers to assess the anti-Dengue immune response.		99 weeks
Secondary	Occurrence and magnitude of anti-DENV-3 total IgG antibody titers to assess the anti-Dengue immune response.		99 weeks
Secondary	Time to first onset of anti-DENV-3 total IgM antibody titers to assess the anti-Dengue immune response.		99 weeks
Secondary	Time to first onset of anti-DENV-3 total IgG antibody titers to assess the anti-Dengue immune response.		99 weeks